Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 115.00
Bid: 114.50
Ask: 121.50
Change: 1.00 (0.88%)
Spread: 7.00 (6.114%)
Open: 114.00
High: 118.00
Low: 114.00
Prev. Close: 114.00
XAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Jul 2021 07:00

RNS Number : 0521G
Xaar PLC
22 July 2021
 

 

 

Xaar plc

 

Trading Update

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology group, today announces a trading update for the six months ended 30 June 2021.

 

TRADING

 

The Board is pleased to announce that trading for the six months ended 30 June 2021 has been in line with its expectations. Revenue for the period is expected to be approximately £26 million, representing an increase of 11% and 8% relative to H1 and H2 2020 respectively.

 

The Printhead business continues to perform well following the ongoing successful roll out of the ImagineX platform and launch of the Xaar Nitrox printhead in April, which is attracting new customers and increased opportunities to broaden the offering in applications where our products are market leading. Whilst we are seeing some COVID-19 related supply constraints, we are taking the required actions to mitigate their impact and continue to be optimistic on the future trading environment.

 

Revenues for the Product Print Systems business (EPS) are in line with management expectations, being below that achieved in H1 2020. Whilst the underlying performance remains on track and the business continues to be profitable, H1 2021 results have been impacted by non-cash adjustments relating to slow moving and obsolete inventory following the implementation of planned process improvement and strategy actions announced at our full year results.

 

Negotiations to divest Xaar's interest in Xaar 3D are now at an advanced stage and a further update will be announced to shareholders in due course.

 

BALANCE SHEET AND LIQUIDITY

 

The Group retains a strong balance sheet and cash position. Net cash at 30 June 2021, excluding cash from the 3D business (which is classified as an asset held for sale) was £17.1 million. This represents a decline of £1.0 million in net cash for continuing operations since 31 December 2020, which has been primarily driven by planned capital investment, including the relocation of Xaar's Cambridge office which will generate £0.7 million of annual cost savings. The Group maintains a strong cash focus and disciplined cost controls.

 

TRADING OUTLOOK

 

Whilst the COVID-19 pandemic continues to have a wider economic impact, our short-term outlook remains positive with a healthy order book across the business. We continue to focus on implementing our strategy to enable future growth and remain on-track to return to profitability in the medium term.

 

We announced on 12 July 2021 the acquisition of FFEI Limited ("FFEI"), a leading integrator and manufacturer of industrial digital inkjet systems and digital life science technology. The addition of FFEI strengthens Xaar's capabilities and skills and will accelerate Xaar's existing growth strategy. 

 

 

John Mills, Chief Executive Officer, commented:

 

"We are pleased with our continued good performance which shows the positive momentum we have in the business. Our strong foundations remain, and we continue to gain new customers and see positive re-engagement with the business as our strategy is proving to work. We are investing in capability and capacity to drive future growth and the addition of FFEI to the Group will provide us with further opportunities to grow the business and accelerate our strategy."

 

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

 

John Mills, Chief Executive Officer

 

 

Tulchan Communications

James Macey White

Giles Kernick

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKDBKFBKDOOB
Date   Source Headline
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company
21st Sep 20239:57 amRNSHolding(s) in Company
19th Sep 20237:00 amRNS2023 Interim Results
11th Sep 20232:11 pmRNSHolding(s) in Company
11th Sep 202312:14 pmRNSHolding(s) in Company
11th Sep 202312:07 pmRNSHolding(s) in Company
11th Sep 202312:03 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
7th Sep 20239:00 amRNSNotice of 2023 Half Year Results
1st Sep 20239:30 amRNSTotal Voting Rights
25th Aug 202312:13 pmRNSHolding(s) in Company
23rd Aug 202310:24 amRNSHolding(s) in Company
18th Aug 202310:30 amRNSChange of Auditor
17th Aug 202312:55 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSTrading Update
1st Aug 20232:00 pmRNSTotal Voting Rights
28th Jul 20234:30 pmRNSHolding(s) in Company
5th Jul 20239:00 amRNSXaar plc - Commercial partnership with Quantica
4th Jul 20233:00 pmRNSBlock listing Interim Review
3rd Jul 20232:53 pmRNSTotal Voting Rights
1st Jun 202310:37 amRNSTotal Voting Rights
31st May 202311:30 amRNSResult of AGM
31st May 20239:00 amRNSBoard Changes
11th May 20235:41 pmRNSHolding(s) in Company
10th May 20233:10 pmRNSDirector/PDMR Shareholding
2nd May 202312:39 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.